How Common GLP-1 Use Is in the United States
An estimated 6% to 9% of U.S. adults have used a GLP-1 receptor agonist, with semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) driving most adoption. Prevalence is highest among adults with obesity or type 2 diabetes and is substantially lower among younger adults and children. Regional variation, payer mix, and lag in prescribing in rural or low-income areas mean national averages mask meaningful disparities. The following sections define GLP-1s, review recent national estimates, and outline how demographic and clinical factors shape usage patterns.
Defining GLP-1 Receptor Agonists
GLP-1 receptor agonists are injectable or oral drugs that mimic the hormone glucagon-like peptide-1 to lower blood sugar, promote satiety, and slow gastric emptying. Originally developed for type 2 diabetes, higher-dose formulations are now used for weight management in adults with obesity or overweight with comorbidities. Common products include:
- Semaglutide (Ozempic subcutaneous; Wegovy subcutaneous)
- Liraglutide (Victoza subcutaneous; Saxenda subcutaneous)
- Dulaglutide (Trulicity subcutaneous)
- Tirzepatide (Mounjaro subcutaneous; Zepbound subcutaneous)
- Oral semaglutide (Rybelsus)
Wegovy and Zepbound are authorized for chronic weight management; Ozemp, Mounjaro, and other variants are commonly prescribed off-label for weight loss when used at higher doses than their labeled indications.
National Estimates and Recent Trends
Nationwide surveys and commercial claims data indicate that GLP-1 use has risen sharply since 2021 but still affects a minority of U.S. adults. Estimates vary by definition (current vs past use, any prescription vs consistent fill) and data source, but key sources include:
- National health interviews and electronic health record studies
- Commercial insurance and pharmacy claims datasets
- Surveys of employer-sponsored and Medicare Part D populations
Consensus across multiple sources points to a prevalence range of roughly 6% to 9% among U.S. adults at a given point in time, with peaks in middle age and higher rates among people with diabetes or obesity. Use remains lower among young adults and is uncommon in children.
Who Is Most Likely to Use GLP-1s
Demographic Patterns
Data consistently show higher utilization among:
- Adults aged 30 to 64 years
- People with type 2 diabetes or a high clinical need for weight management
- Individuals with higher income or better insurance coverage, particularly when prior authorization and cost-sharing are manageable
Younger adults, those without diagnosed cardiometabolic conditions, and populations facing access barriers report lower use. Rural residents and some historically underserved groups experience prescribing gaps.
Clinical Indications and Comorbidities
The strongest drivers of GLP-1 use are:
- Type 2 diabetes requiring additional glucose-lowering agents
- Obesity (BMI 30+ or BMI 27+ with comorbidities), where GLP-1s have demonstrated robust weight loss
- Cardiovascular risk reduction, particularly in people with prior atherosclerotic cardiovascular disease
Use is much less common among people whose care plans do not align with these indications, reflecting guideline-driven prescribing and payer policies.
How Estimates Are Measured and Why They Vary
Prevalence estimates depend on definitions and data sources. Common approaches include:
| Metric | Verified Detail | Source Type |
|---|---|---|
| Ever use (12 months) | 6–9% of U.S. adults | Claims and survey data |
| Current regular use (≥80% days covered) | 3–5% of U.S. adults | Pharmacy adherence studies |
| Higher prevalence in adults with diabetes | 1 in 4 to 1 in 3 may have used a GLP-1 | Disease registries and EHRs |
| Higher prevalence in adults with obesity | 1 in 5 to 1 in 4 may have used a GLP-1 | Market research and payer data |
Time periods, inclusion of off-label use, and whether the estimate reflects any fill versus sustained use explain variation across studies. Geographic variation within the United States can be substantial, with higher rates in some metropolitan areas and lower rates in rural or low-income regions.
Geographic Variation and Access Barriers
GLP-1 utilization is not evenly distributed. Areas with more endocrinologists, weight-management clinics, and integrated health systems often show higher rates of prescribing. Conversely, rural counties and regions with fewer specialty providers report lower use even when demand exists. Factors include:
- Provider knowledge and familiarity with guidelines
- Formulary restrictions and prior authorization requirements
- Transportation and clinic availability
- Cost-sharing and patient affordability after deductibles
Recent policy expansions, including telehealth prescribing for weight-loss medications, have improved access for some, but gaps persist.
Implications for Use and Misuse in Public Discourse
High-profile anecdotes and social media trends can make GLP-1 use seem more universal than data indicate. In reality, the majority of U.S. adults are not currently using these drugs. Within the user population, misuse or suboptimal use can occur when prescriptions are obtained without appropriate medical oversight or when people pursue these medications solely for cosmetic weight loss without addressing underlying health conditions. Clinicians typically reserve GLP-1s for people who meet clinical criteria or have substantial cardiometabolic risk, aligning use with evidence-based guidelines.
Future Directions and Data Gaps
Ongoing monitoring will be important as:
- Newer fixed-dose combinations and oral formulations increase convenience
- Payer policies evolve in response to cost and demand
- Long-term safety and cardiovascular outcomes data accrue
- Disparities in access are addressed through policy and delivery models
For now, the best available estimates suggest that roughly 6% to 9% of U.S. adults have used a GLP-1, with substantially lower rates of current, consistent use. These drugs are powerful tools for eligible patients but remain concentrated among specific clinical groups and care settings.
Key Takeaways
- Approximately 6% to 9% of U.S. adults have used a GLP-1 medication, according to aggregated claims and survey evidence.
- Current regular use is lower, estimated around 3% to 5%, reflecting adherence patterns and prescribing practices.
- Use is highest among adults with type 2 diabetes, obesity, and cardiovascular disease, and among middle-aged adults with adequate access to care.
- Geographic, economic, and supply-side factors create meaningful disparities in who can consistently obtain these medications.
- Public perceptions of widespread use often exceed the data; most U.S. adults are not on a GLP-1.